Novo Nordisk A/S — Sponsor Intelligence | 107 EU Trials

Filter these 107 trials by condition, phase, country and more.

Open in Search →

107 Registered trials

29 Recruiting

72 Completed trials

25 Countries active

40 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 49 Phase II/III: 1 Phase II: 13 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I: 13 Phase I (Other): 24 Other: 3

Oversight events:

11 serious breaches 1 temporary halt 1 corrective measure across 9 trials

View oversight register →

100%

72 of 72 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Obesity 9 Sickle cell disease 3 Overweight 2 Cardiac failure 2 Non-alcoholic steatohepatitis 2 Acute myocardial infarction 1 Chronic kidney disease 1 Type 2 diabetes mellitus 1 Cardiovascular disorder 1 Turner's syndrome 1 Noonan syndrome 1 Alcoholic liver disease 1

Top IMPs

SEMAGLUTIDE 19 CAGRILINTIDE, SEMAGLUTIDE 12 ZENAGAMTIDE 9 CAGRILINTIDE 7 INSULIN GLARGINE 5 ZILTIVEKIMAB 5 ETAVOPIVAT 4 INSULIN ICODEC 4 SOMAPACITAN 4 CORAMITUG 3 SOMATROPIN 3 CONCIZUMAB 2

All trials — page 3

107 total

HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Phase III 24 countries ZILTIVEKIMAB
A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended

2022-502215-10-00 Phase III 16 countries DENECIMIG
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended

2023-506924-94-00 Phase III 9 countries CAGRILINTIDE, SEMAGLUTIDE
A research study to see how well CagriSema helps people with excess body weight lose weight Ended

2023-506929-11-00 Phase III 10 countries
A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended

2023-506927-27-00 Phase III 16 countries SOMAPACITAN; SOMATROPIN
This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients, age 12 to 65 years, with sickle cell … Ended

2024-511535-97-00 Phase II/III 5 countries ETAVOPIVAT
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Phase III 18 countries ZILTIVEKIMAB
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Phase III 18 countries SEMAGLUTIDE
A research study on how well liraglutide works in children with obesity Ended

2023-508504-38-00 Phase III 2 countries LIRAGLUTIDE
Research study to look at how well the drug Concizumab works in your body if you have haemophilia without inhibitors Ended

2023-506831-13-00 Phase III 11 countries CONCIZUMAB
Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors Ended

2023-506832-33-00 Phase III 8 countries CONCIZUMAB
A research study in children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day Ended

2023-506830-66-00 Phase II 5 countries SOMAPACITAN; SOMATROPIN
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended

2023-506827-26-00 Phase III 10 countries SEMAGLUTIDE
A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes Ended

2025-521593-33-00 Phase I (Other) 1 country
A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump. Ended

2024-520230-29-00 Phase I (Other) 1 country
A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatmen… Ended

2024-519478-38-00 Phase I 1 country
A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity Ended

2023-508940-23-01 Phase I (Other) 1 country
A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump. Ended

2024-513472-18-00 Phase I (Other) 1 country
A research study of a new medicine NNC0363-1063 in healthy participants and participants with type 1 diabetes Ended

2024-511808-17-00 Phase I 1 country
A research study on the effects of NNC0537-1482 in healthy individuals when injected under the skin. Ended

2024-514431-18-00 Phase I 1 country
A research study looking at how different doses of study medicine (Inno8) works in the body of healthy men. Ended

2023-506520-90-00 Phase I 1 country
A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemo… Ended

2023-504574-38-00 Phase I (Other) 1 country
A research study to see how well different doses of CagriSema help people with excess body weight lose weight Ended

2023-509273-24-00 Phase III 2 countries CAGRILINTIDE, SEMAGLUTIDE
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 Phase II 10 countries CAGRILINTIDE; CAGRILINTIDE, SEMAGLUTIDE; SEMAGLUTIDE; ZALFERMIN

Showing 49–72 of 107 trials

← All sponsors A–Z